Core Viewpoint - Jingyin Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs, Haitong International, and HSBC acting as joint sponsors [1] Company Overview - Jingyin Pharmaceutical is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies. The company aims to innovate treatment standards for chronic diseases through its proprietary siRNA technology platform and global collaboration network [4][5] - The siRNA therapy market is projected to reach USD 2.4 billion in 2024 and grow to USD 50.3 billion by 2040, with a compound annual growth rate (CAGR) of 20.9% [4] Product Pipeline - The company is advancing three major product pipelines targeting coagulation disorders, cardiovascular metabolic diseases, and obesity, each with significant market potential. In 2024, these therapeutic areas are expected to have at least one blockbuster drug with annual sales exceeding USD 10 billion [5] - Key pipeline products include: - SRSD107: A potential first-in-class siRNA drug targeting coagulation factor XI, currently in Phase II clinical trials in Europe and planned for trials in China and Australia/New Zealand - SRSD216: A potential best-in-class siRNA targeting Lp(a), undergoing Phase IIa trials in China and the U.S. - SRSD384: An INHBE-targeting candidate for obesity, with promising preclinical data and active IND application [5] Financial Performance - For the six months ending June 30, 2023, 2024, and 2025, the company reported other income and revenue of approximately RMB 8.81 million, RMB 9.79 million, and RMB 14.4 million, respectively. The net loss for the same periods was approximately RMB 309 million, RMB 342 million, and RMB 34.5 million [6][7] - Administrative expenses and R&D expenses for the same periods were RMB 25.56 million, RMB 22.71 million, and RMB 233.42 million, RMB 213.33 million, respectively [7]
靖因药业递表港交所 以siRNA疗法赋能慢性病管理范式转变
Zhi Tong Cai Jing·2025-09-28 23:22